• News
  • BioTech

Polaris Group files IND for leukemia treatment

San Diego’s Polaris Group announced Monday that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!